Autonomix (AMIX) Medical recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, CMO, discussed the Company’s recently announced 4-6 week positive follow-up data, from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMIX: